Arpida Provides Further Comments On The Pivotal Phase III Trials
Further to the press release published on 9 April, Arpida Ltd. (SWX: ARPN) elaborates on some additional elements of the clinical programme with intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI). Extensive data on ASSIST-1 has been presented at last year’s ICAAC and IDSA meetings.
This post is an original post by ScienceDaily: Skin Care News
Posted: April 12th, 2008 under skin health.
Comments: none
